|
US7013219B2
(en)
*
|
1999-01-12 |
2006-03-14 |
Sangamo Biosciences, Inc. |
Regulation of endogenous gene expression in cells using zinc finger proteins
|
|
US20030104526A1
(en)
|
1999-03-24 |
2003-06-05 |
Qiang Liu |
Position dependent recognition of GNN nucleotide triplets by zinc fingers
|
|
US7030215B2
(en)
*
|
1999-03-24 |
2006-04-18 |
Sangamo Biosciences, Inc. |
Position dependent recognition of GNN nucleotide triplets by zinc fingers
|
|
US20020164575A1
(en)
*
|
1999-09-14 |
2002-11-07 |
Sangamo Biosciences, Inc., A Delaware Corporation |
Gene identification
|
|
DE60023936T2
(de)
*
|
1999-12-06 |
2006-05-24 |
Sangamo Biosciences Inc., Richmond |
Methoden zur verwendung von randomisierten zinkfingerprotein-bibliotheken zur identifizierung von genfunktionen
|
|
US20020061512A1
(en)
*
|
2000-02-18 |
2002-05-23 |
Kim Jin-Soo |
Zinc finger domains and methods of identifying same
|
|
US20020055112A1
(en)
*
|
2000-08-26 |
2002-05-09 |
Nila Patil |
Methods for reducing complexity of nucleic acid samples
|
|
US20020164634A1
(en)
*
|
2000-08-26 |
2002-11-07 |
Perlegen Sciences, Inc. |
Methods for reducing complexity of nucleic acid samples
|
|
CA2434881A1
(en)
*
|
2001-02-02 |
2002-08-15 |
Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. |
Method for identifying functional nucleic acids
|
|
JP4128955B2
(ja)
*
|
2001-08-17 |
2008-07-30 |
トゥールゲン・インコーポレイテッド |
ジンクフィンガードメインライブラリー
|
|
CN100463962C
(zh)
*
|
2001-12-07 |
2009-02-25 |
图尔金株式会社 |
嵌合蛋白质的表型筛选
|
|
US20040259258A1
(en)
*
|
2001-12-07 |
2004-12-23 |
Kim Jin-Soo |
Regulation of prokaryotic gene expression with zinc finger proteins
|
|
EP1476547B1
(de)
|
2002-01-23 |
2006-12-06 |
The University of Utah Research Foundation |
Zielgerichtete chromosomale mutagenese mit zinkfingernukleasen
|
|
WO2003066828A2
(en)
*
|
2002-02-07 |
2003-08-14 |
The Scripps Research Institute |
Zinc finger libraries
|
|
US20030180777A1
(en)
*
|
2002-03-12 |
2003-09-25 |
Victor Bartsevich |
Rapid identification of transcriptional regulatory domains
|
|
AU2003260973A1
(en)
*
|
2002-09-05 |
2004-03-29 |
Toolgen, Inc. |
Bioinformatics analysis of cellular effects of artificial transcription factors
|
|
EP1581610A4
(de)
|
2002-09-05 |
2009-05-27 |
California Inst Of Techn |
Verwendung chimerer nukleasen zur stimulierung des gen-targeting
|
|
US20050069896A1
(en)
*
|
2002-09-12 |
2005-03-31 |
Horvitz H. Robert |
Rb pathway and chromatin remodeling genes that antagonize let-60 Ras signaling
|
|
US20070178454A1
(en)
*
|
2002-10-21 |
2007-08-02 |
Joung J K |
Context sensitive paralell optimization of zinc finger dna binding domains
|
|
AU2003304087A1
(en)
*
|
2002-10-23 |
2004-11-26 |
The General Hospital Corporation |
Methods for producing zinc finger proteins that bind to extended dna target sequences
|
|
AU2003295692A1
(en)
*
|
2002-11-15 |
2004-06-15 |
Sangamo Biosciences, Inc. |
Methods and compositions for analysis of regulatory sequences
|
|
EP1570058A1
(de)
*
|
2002-12-09 |
2005-09-07 |
Toolgen, Inc. |
Regulatorische zinkfingerproteine
|
|
US20090124514A1
(en)
*
|
2003-02-26 |
2009-05-14 |
Perlegen Sciences, Inc. |
Selection probe amplification
|
|
US20060183132A1
(en)
*
|
2005-02-14 |
2006-08-17 |
Perlegen Sciences, Inc. |
Selection probe amplification
|
|
US20050100911A1
(en)
*
|
2003-08-06 |
2005-05-12 |
Perlegen Sciences, Inc. |
Methods for enriching populations of nucleic acid samples
|
|
US20120196370A1
(en)
|
2010-12-03 |
2012-08-02 |
Fyodor Urnov |
Methods and compositions for targeted genomic deletion
|
|
US8409861B2
(en)
|
2003-08-08 |
2013-04-02 |
Sangamo Biosciences, Inc. |
Targeted deletion of cellular DNA sequences
|
|
US11311574B2
(en)
|
2003-08-08 |
2022-04-26 |
Sangamo Therapeutics, Inc. |
Methods and compositions for targeted cleavage and recombination
|
|
US7888121B2
(en)
|
2003-08-08 |
2011-02-15 |
Sangamo Biosciences, Inc. |
Methods and compositions for targeted cleavage and recombination
|
|
US7972854B2
(en)
|
2004-02-05 |
2011-07-05 |
Sangamo Biosciences, Inc. |
Methods and compositions for targeted cleavage and recombination
|
|
US20060063231A1
(en)
*
|
2004-09-16 |
2006-03-23 |
Sangamo Biosciences, Inc. |
Compositions and methods for protein production
|
|
EP1910307A1
(de)
|
2005-06-27 |
2008-04-16 |
Exelixis, Inc. |
Lxr-modulatoren auf pyrazolbasis
|
|
US7718131B2
(en)
*
|
2005-07-06 |
2010-05-18 |
Genetix Limited |
Methods and apparatus for imaging and processing of samples in biological sample containers
|
|
US20070148674A1
(en)
*
|
2005-12-23 |
2007-06-28 |
Wisconsin Alumni Research Foundation (Warf) |
Optical fingerprinting of nucleic acid sequences
|
|
WO2007106603A2
(en)
*
|
2006-01-06 |
2007-09-20 |
The Scripps Research Institute |
Specific labeling of proteins with zinc finger tags and use of zinc-finger-tagged proteins for analysis
|
|
KR100756055B1
(ko)
*
|
2006-01-27 |
2007-09-07 |
연세대학교 산학협력단 |
신생혈관 생성을 조절하는 재조합 아데노바이러스
|
|
US7763441B2
(en)
|
2006-03-13 |
2010-07-27 |
Wyeth |
Modulators of gluconeogenesis
|
|
AU2007254251A1
(en)
*
|
2006-05-19 |
2007-11-29 |
Sangamo Therapeutics, Inc. |
Methods and compositions for inactivation of dihydrofolate reductase
|
|
WO2007139982A2
(en)
|
2006-05-25 |
2007-12-06 |
Sangamo Biosciences, Inc. |
Methods and compositions for gene inactivation
|
|
JP5266210B2
(ja)
|
2006-05-25 |
2013-08-21 |
サンガモ バイオサイエンシズ インコーポレイテッド |
改変開裂ハーフドメイン
|
|
US9428756B2
(en)
|
2006-08-11 |
2016-08-30 |
Dow Agrosciences Llc |
Zinc finger nuclease-mediated homologous recombination
|
|
CA2667414C
(en)
*
|
2006-11-13 |
2015-12-29 |
Sangamo Biosciences, Inc. |
Methods and compositions for modification of the human glucocorticoid receptor locus
|
|
EP2171052B1
(de)
*
|
2007-07-12 |
2014-08-27 |
Sangamo BioSciences, Inc. |
Verfahren und zusammensetzung zur deaktivierung der alpha-1,6-fucosyltransferase-genexpression
|
|
HRP20161004T1
(hr)
*
|
2007-09-27 |
2016-10-21 |
Dow Agrosciences Llc |
Tehnološki konstruirani proteini cinkovi prsti koji imaju kao cilj gene za sintazu 5-enolpiruvilshikimat-3-fosfata
|
|
AU2008305590A1
(en)
*
|
2007-09-27 |
2009-04-02 |
Sangamo Therapeutics, Inc. |
Genomic editing in zebrafish using zinc finger nucleases
|
|
US8563314B2
(en)
|
2007-09-27 |
2013-10-22 |
Sangamo Biosciences, Inc. |
Methods and compositions for modulating PD1
|
|
US8936936B2
(en)
|
2007-10-25 |
2015-01-20 |
Sangamo Biosciences, Inc. |
Methods and compositions for targeted integration
|
|
WO2009146179A1
(en)
*
|
2008-04-15 |
2009-12-03 |
University Of Iowa Research Foundation |
Zinc finger nuclease for the cftr gene and methods of use thereof
|
|
EP2294191B1
(de)
|
2008-06-10 |
2016-09-28 |
Sangamo BioSciences, Inc. |
Verfahren und zusammensetzungen zur erzeugung von bax- und bak-mangel-zelllinien
|
|
CA2734235C
(en)
|
2008-08-22 |
2019-03-26 |
Sangamo Biosciences, Inc. |
Methods and compositions for targeted single-stranded cleavage and targeted integration
|
|
US8153399B2
(en)
|
2008-10-29 |
2012-04-10 |
Sangamo Biosciences, Inc. |
Methods and compositions for inactivating glutamine synthetase gene expression
|
|
US9206404B2
(en)
|
2008-12-04 |
2015-12-08 |
Sangamo Biosciences, Inc. |
Method of deleting an IgM gene in an isolated rat cell
|
|
US8551945B2
(en)
*
|
2009-02-04 |
2013-10-08 |
Sangamo Biosciences, Inc. |
Methods and compositions for treating neuropathies
|
|
WO2010107493A2
(en)
|
2009-03-20 |
2010-09-23 |
Sangamo Biosciences, Inc. |
Modification of cxcr4 using engineered zinc finger proteins
|
|
AU2010235161B2
(en)
*
|
2009-04-09 |
2015-01-22 |
Sangamo Therapeutics, Inc. |
Targeted integration into stem cells
|
|
WO2011016840A2
(en)
*
|
2009-07-28 |
2011-02-10 |
Sangamo Biosciences, Inc. |
Methods and compositions for treating trinucleotide repeat disorders
|
|
US8956828B2
(en)
|
2009-11-10 |
2015-02-17 |
Sangamo Biosciences, Inc. |
Targeted disruption of T cell receptor genes using engineered zinc finger protein nucleases
|
|
JP5902631B2
(ja)
|
2010-01-22 |
2016-04-13 |
ダウ アグロサイエンシィズ エルエルシー |
標的化ゲノム変更
|
|
CA2788560A1
(en)
|
2010-02-08 |
2011-08-11 |
Sangamo Biosciences, Inc. |
Engineered cleavage half-domains
|
|
WO2011100058A1
(en)
|
2010-02-09 |
2011-08-18 |
Sangamo Biosciences, Inc. |
Targeted genomic modification with partially single-stranded donor molecules
|
|
EP2563918B1
(de)
|
2010-04-26 |
2016-11-23 |
Sangamo BioSciences, Inc. |
Genombearbeitung des rosa26-lokus mithilfe von zinkfinger-nukleasen
|
|
CN103025344B
(zh)
|
2010-05-17 |
2016-06-29 |
桑格摩生物科学股份有限公司 |
新型dna-结合蛋白及其用途
|
|
US8945868B2
(en)
|
2010-07-21 |
2015-02-03 |
Sangamo Biosciences, Inc. |
Methods and compositions for modification of a HLA locus
|
|
CA2811364C
(en)
|
2010-09-27 |
2022-01-04 |
Sangamo Biosciences, Inc. |
Methods and compositions for inhibiting viral entry into cells
|
|
JP6018069B2
(ja)
|
2010-10-12 |
2016-11-02 |
ザ・チルドレンズ・ホスピタル・オブ・フィラデルフィアThe Children’S Hospital Of Philadelphia |
血友病bを治療する方法及び組成物
|
|
US9267123B2
(en)
|
2011-01-05 |
2016-02-23 |
Sangamo Biosciences, Inc. |
Methods and compositions for gene correction
|
|
CA2841710C
(en)
|
2011-07-15 |
2021-03-16 |
The General Hospital Corporation |
Methods of transcription activator like effector assembly
|
|
EP2734621B1
(de)
|
2011-07-22 |
2019-09-04 |
President and Fellows of Harvard College |
Beurteilung und verbesserung einer nukleasespaltungsspezifität
|
|
US9161995B2
(en)
|
2011-07-25 |
2015-10-20 |
Sangamo Biosciences, Inc. |
Methods and compositions for alteration of a cystic fibrosis transmembrane conductance regulator (CFTR) gene
|
|
EP3498833B1
(de)
|
2011-09-21 |
2023-08-16 |
Sangamo Therapeutics, Inc. |
Verfahren und zusammensetzungen zur regulierung der transgenexpression
|
|
CA2852955C
(en)
|
2011-10-27 |
2021-02-16 |
Sangamo Biosciences, Inc. |
Methods and compositions for modification of the hprt locus
|
|
CA2854819C
(en)
|
2011-11-16 |
2022-07-19 |
Sangamo Biosciences, Inc. |
Modified dna-binding proteins and uses thereof
|
|
MX374399B
(es)
|
2012-02-29 |
2025-03-06 |
Sangamo Biosciences Inc |
Composiciones y sus usos para tratar y prevenir la enfermedad de huntington.
|
|
SG11201406547YA
(en)
|
2012-04-25 |
2014-11-27 |
Regeneron Pharma |
Nuclease-mediated targeting with large targeting vectors
|
|
JP6352250B2
(ja)
*
|
2012-05-02 |
2018-07-04 |
ダウ アグロサイエンシィズ エルエルシー |
リンゴ酸デヒドロゲナーゼの標的改変
|
|
CA2871524C
(en)
|
2012-05-07 |
2021-07-27 |
Sangamo Biosciences, Inc. |
Methods and compositions for nuclease-mediated targeted integration of transgenes
|
|
US9890364B2
(en)
|
2012-05-29 |
2018-02-13 |
The General Hospital Corporation |
TAL-Tet1 fusion proteins and methods of use thereof
|
|
US10648001B2
(en)
|
2012-07-11 |
2020-05-12 |
Sangamo Therapeutics, Inc. |
Method of treating mucopolysaccharidosis type I or II
|
|
US10883119B2
(en)
|
2012-07-11 |
2021-01-05 |
Sangamo Therapeutics, Inc. |
Methods and compositions for delivery of biologics
|
|
CA2875618C
(en)
|
2012-07-11 |
2021-04-27 |
Sangamo Biosciences, Inc. |
Methods and compositions for the treatment of lysosomal storage diseases
|
|
SG11201500852WA
(en)
|
2012-08-29 |
2015-04-29 |
Sangamo Biosciences Inc |
Methods and compositions for treatment of a genetic condition
|
|
JP6442406B2
(ja)
|
2012-09-04 |
2018-12-19 |
ザ スクリプス リサーチ インスティテュート |
標的結合特異性を有するキメラポリペプチド
|
|
UA118090C2
(uk)
|
2012-09-07 |
2018-11-26 |
ДАУ АГРОСАЙЄНСІЗ ЕлЕлСі |
Спосіб інтегрування послідовності нуклеїнової кислоти, що представляє інтерес, у ген fad2 у клітині сої та специфічний для локусу fad2 білок, що зв'язується, здатний індукувати спрямований розрив
|
|
UA119135C2
(uk)
|
2012-09-07 |
2019-05-10 |
ДАУ АГРОСАЙЄНСІЗ ЕлЕлСі |
Спосіб отримання трансгенної рослини
|
|
HK1217732A1
(zh)
|
2012-09-07 |
2017-01-20 |
美国陶氏益农公司 |
Fad3性能基因座及相應的能夠誘導靶向斷裂的靶位點特異性結合蛋白
|
|
EP2906684B8
(de)
|
2012-10-10 |
2020-09-02 |
Sangamo Therapeutics, Inc. |
T-zell-modifizierende verbindungen und verwendungen davon
|
|
EP3789405A1
(de)
|
2012-10-12 |
2021-03-10 |
The General Hospital Corporation |
Transkriptionsaktivator-like-effektor-lysinspezifische demethylase-1 (lsd1)-fusionsproteine
|
|
EP2929017A4
(de)
|
2012-12-05 |
2016-09-28 |
Sangamo Biosciences Inc |
Verfahren und zusammensetzungen zur regulierung von stoffwechselerkrankungen
|
|
US10272163B2
(en)
|
2012-12-07 |
2019-04-30 |
The Regents Of The University Of California |
Factor VIII mutation repair and tolerance induction
|
|
EP2954042B1
(de)
|
2013-02-07 |
2017-12-06 |
The General Hospital Corporation |
Tale-transkriptionsaktivatoren
|
|
EP2958996B1
(de)
|
2013-02-25 |
2019-10-16 |
Sangamo Therapeutics, Inc. |
Verfahren und zusammensetzungen zur verbesserung einer nuklease-vermittelten genunterbrechung
|
|
US9885033B2
(en)
|
2013-03-15 |
2018-02-06 |
The General Hospital Corporation |
Increasing specificity for RNA-guided genome editing
|
|
US10760064B2
(en)
|
2013-03-15 |
2020-09-01 |
The General Hospital Corporation |
RNA-guided targeting of genetic and epigenomic regulatory proteins to specific genomic loci
|
|
US11332719B2
(en)
*
|
2013-03-15 |
2022-05-17 |
The Broad Institute, Inc. |
Recombinant virus and preparations thereof
|
|
AU2014235968B2
(en)
|
2013-03-21 |
2018-05-24 |
Ospedale San Raffaele Srl |
Targeted disruption of T cell receptor genes using engineered zinc finger protein nucleases
|
|
SG10201808935WA
(en)
|
2013-04-16 |
2018-11-29 |
Regeneron Pharma |
Targeted modification of rat genome
|
|
JP2016518142A
(ja)
|
2013-05-10 |
2016-06-23 |
サンガモ バイオサイエンシーズ, インコーポレイテッド |
ヌクレアーゼ媒介ゲノム遺伝子操作のための送達方法および組成物
|
|
HK1223401A1
(zh)
|
2013-05-15 |
2017-07-28 |
桑格摩生物科学股份有限公司 |
用於治疗遗传病状的方法和组合物
|
|
US10011850B2
(en)
|
2013-06-21 |
2018-07-03 |
The General Hospital Corporation |
Using RNA-guided FokI Nucleases (RFNs) to increase specificity for RNA-Guided Genome Editing
|
|
US20150044192A1
(en)
|
2013-08-09 |
2015-02-12 |
President And Fellows Of Harvard College |
Methods for identifying a target site of a cas9 nuclease
|
|
US9359599B2
(en)
|
2013-08-22 |
2016-06-07 |
President And Fellows Of Harvard College |
Engineered transcription activator-like effector (TALE) domains and uses thereof
|
|
JP6588438B2
(ja)
|
2013-08-28 |
2019-10-09 |
サンガモ セラピューティクス, インコーポレイテッド |
Dna結合ドメインと切断ドメインとを連結するための組成物
|
|
US9388430B2
(en)
|
2013-09-06 |
2016-07-12 |
President And Fellows Of Harvard College |
Cas9-recombinase fusion proteins and uses thereof
|
|
US9526784B2
(en)
|
2013-09-06 |
2016-12-27 |
President And Fellows Of Harvard College |
Delivery system for functional nucleases
|
|
US9340800B2
(en)
|
2013-09-06 |
2016-05-17 |
President And Fellows Of Harvard College |
Extended DNA-sensing GRNAS
|
|
EP3057432B1
(de)
|
2013-10-17 |
2018-11-21 |
Sangamo Therapeutics, Inc. |
Verfahren und zusammensetzungen für nukleasevermitteltes genom-engineering in hämotopoietischen stammzellen
|
|
CN110713995B
(zh)
|
2013-10-17 |
2023-08-01 |
桑格摩生物科学股份有限公司 |
用于核酸酶介导的基因组工程改造的递送方法和组合物
|
|
UA120503C2
(uk)
|
2013-11-04 |
2019-12-26 |
Дау Агросайєнсиз Елелсі |
Спосіб одержання трансгенної клітини рослини кукурудзи
|
|
EP3862434A1
(de)
|
2013-11-04 |
2021-08-11 |
Dow AgroSciences LLC |
Optimale sojabohnen-loci
|
|
UY35812A
(es)
|
2013-11-04 |
2015-05-29 |
Dow Agrosciences Llc |
?loci de maíz óptimos?.
|
|
CA2930015A1
(en)
|
2013-11-07 |
2015-05-14 |
Editas Medicine, Inc. |
Crispr-related methods and compositions with governing grnas
|
|
EP3068905A4
(de)
|
2013-11-11 |
2017-07-05 |
Sangamo BioSciences, Inc. |
Verfahren und zusammensetzungen zur behandlung der huntington-krankheit
|
|
ES2895069T3
(es)
|
2013-11-13 |
2022-02-17 |
Childrens Medical Center |
Regulación de la expresión génica mediada por nucleasa
|
|
CA3229275A1
(en)
|
2013-12-09 |
2015-06-18 |
Sangamo Biosciences, Inc. |
Methods and compositions for genome engineering
|
|
JP6174811B2
(ja)
|
2013-12-11 |
2017-08-02 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッドRegeneron Pharmaceuticals, Inc. |
ゲノムの標的改変のための方法及び組成物
|
|
US9840699B2
(en)
|
2013-12-12 |
2017-12-12 |
President And Fellows Of Harvard College |
Methods for nucleic acid editing
|
|
DK3102673T3
(da)
|
2014-02-03 |
2020-07-06 |
Sangamo Therapeutics Inc |
Fremgangsmåder og sammensætninger til behandling af beta-talassæmi
|
|
CA2939942A1
(en)
|
2014-02-24 |
2015-08-27 |
Sangamo Biosciences, Inc. |
Methods and compositions for nuclease-mediated targeted integration
|
|
EP3119878B1
(de)
|
2014-03-18 |
2021-05-26 |
Sangamo Therapeutics, Inc. |
Verfahren und zusammensetzungen zur regulierung der zinkfingerproteinexpression
|
|
US9522936B2
(en)
|
2014-04-24 |
2016-12-20 |
Sangamo Biosciences, Inc. |
Engineered transcription activator like effector (TALE) proteins
|
|
AU2015255877B2
(en)
|
2014-05-08 |
2020-03-26 |
Chdi Foundation, Inc. |
Methods and compositions for treating huntington's disease
|
|
WO2015175642A2
(en)
|
2014-05-13 |
2015-11-19 |
Sangamo Biosciences, Inc. |
Methods and compositions for prevention or treatment of a disease
|
|
EP3152319A4
(de)
|
2014-06-05 |
2017-12-27 |
Sangamo BioSciences, Inc. |
Verfahren und zusammensetzungen zur nukleasekonstruktion
|
|
MX385689B
(es)
|
2014-06-06 |
2025-03-18 |
Regeneron Pharma |
Métodos y composiciones para modificar un locus dirigido.
|
|
ES2888976T3
(es)
|
2014-06-23 |
2022-01-10 |
Massachusetts Gen Hospital |
Identificación no sesgada pangenómica de DSBs evaluada por secuenciación (GUIDE-Seq.)
|
|
WO2015200805A2
(en)
|
2014-06-26 |
2015-12-30 |
Regeneron Pharmaceuticals, Inc. |
Methods and compositions for targeted genetic modifications and methods of use
|
|
EA039787B1
(ru)
|
2014-07-14 |
2022-03-14 |
Вашингтон Стейт Юниверсити |
Сельскохозяйственное животное с абляцией клеток зародышевой линии и способы его получения
|
|
MX2017000646A
(es)
|
2014-07-15 |
2017-04-27 |
Juno Therapeutics Inc |
Celulas geneticamente modificadas para terapia celular adoptiva.
|
|
WO2016014837A1
(en)
|
2014-07-25 |
2016-01-28 |
Sangamo Biosciences, Inc. |
Gene editing for hiv gene therapy
|
|
US9816074B2
(en)
|
2014-07-25 |
2017-11-14 |
Sangamo Therapeutics, Inc. |
Methods and compositions for modulating nuclease-mediated genome engineering in hematopoietic stem cells
|
|
WO2016019144A2
(en)
|
2014-07-30 |
2016-02-04 |
Sangamo Biosciences, Inc. |
Gene correction of scid-related genes in hematopoietic stem and progenitor cells
|
|
WO2016022363A2
(en)
|
2014-07-30 |
2016-02-11 |
President And Fellows Of Harvard College |
Cas9 proteins including ligand-dependent inteins
|
|
AU2015317793B2
(en)
|
2014-09-16 |
2021-11-11 |
Sangamo Therapeutics, Inc. |
Methods and compositions for nuclease-mediated genome engineering and correction in hematopoietic stem cells
|
|
KR102630014B1
(ko)
|
2014-10-01 |
2024-01-25 |
더 제너럴 하스피탈 코포레이션 |
뉴클레아제-유도 상동성-지정 복구의 효율 증가 방법
|
|
ES2731437T3
(es)
|
2014-11-21 |
2019-11-15 |
Regeneron Pharma |
Métodos y composiciones para la modificación genética dirigida mediante el uso de pares de ARN guías
|
|
US10889834B2
(en)
|
2014-12-15 |
2021-01-12 |
Sangamo Therapeutics, Inc. |
Methods and compositions for enhancing targeted transgene integration
|
|
MX388784B
(es)
|
2014-12-19 |
2025-03-20 |
Regeneron Pharma |
Métodos y composiciones para la modificación genética dirigida a través de direccionamiento múltiple de una sola etapa.
|
|
US20180002379A1
(en)
|
2015-01-21 |
2018-01-04 |
Sangamo Therapeutics, Inc. |
Methods and compositions for identification of highly specific nucleases
|
|
AU2016243052C1
(en)
|
2015-04-03 |
2022-11-24 |
Dana-Farber Cancer Institute, Inc. |
Composition and methods of genome editing of B-cells
|
|
US10179918B2
(en)
|
2015-05-07 |
2019-01-15 |
Sangamo Therapeutics, Inc. |
Methods and compositions for increasing transgene activity
|
|
BR112017024115A2
(pt)
|
2015-05-12 |
2018-08-07 |
Sangamo Therapeutics Inc |
regulação de expressão genética mediada por nuclease
|
|
EP3302525A2
(de)
|
2015-06-05 |
2018-04-11 |
Novartis AG |
Verfahren und zusammensetzungen zur diagnose, behandlung und überwachung der behandlung von shank3-mangelbedingten erkrankungen
|
|
US9957501B2
(en)
|
2015-06-18 |
2018-05-01 |
Sangamo Therapeutics, Inc. |
Nuclease-mediated regulation of gene expression
|
|
EP3322297B1
(de)
|
2015-07-13 |
2024-12-04 |
Sangamo Therapeutics, Inc. |
Freisetzungsverfahren und zusammensetzungen für nukleasevermitteltes genomengineering
|
|
MA42895A
(fr)
|
2015-07-15 |
2018-05-23 |
Juno Therapeutics Inc |
Cellules modifiées pour thérapie cellulaire adoptive
|
|
JP2018525000A
(ja)
|
2015-08-06 |
2018-09-06 |
ザ・キュレーターズ・オブ・ザ・ユニバーシティ・オブ・ミズーリThe Curators Of The University Of Missouri |
改変cd163遺伝子を有する病原体抵抗性動物
|
|
US9512446B1
(en)
|
2015-08-28 |
2016-12-06 |
The General Hospital Corporation |
Engineered CRISPR-Cas9 nucleases
|
|
US9926546B2
(en)
|
2015-08-28 |
2018-03-27 |
The General Hospital Corporation |
Engineered CRISPR-Cas9 nucleases
|
|
CN108350453A
(zh)
|
2015-09-11 |
2018-07-31 |
通用医疗公司 |
核酸酶dsb的完全查询和测序(find-seq)
|
|
US10435441B2
(en)
|
2015-09-23 |
2019-10-08 |
Sangamo Therapeutics, Inc. |
HTT repressors and uses thereof
|
|
CA3000762A1
(en)
|
2015-09-30 |
2017-04-06 |
The General Hospital Corporation |
Comprehensive in vitro reporting of cleavage events by sequencing (circle-seq)
|
|
IL258821B
(en)
|
2015-10-23 |
2022-07-01 |
Harvard College |
Nucleobase editors and their uses
|
|
CN115141836B
(zh)
|
2015-10-28 |
2024-08-27 |
桑格摩生物治疗股份有限公司 |
肝特异性构建体、因子viii表达盒及其使用方法
|
|
JP6976249B2
(ja)
|
2015-11-23 |
2021-12-08 |
サンガモ セラピューティクス, インコーポレイテッド |
免疫を工学操作するための方法および組成物
|
|
AU2016369490C1
(en)
|
2015-12-18 |
2021-12-23 |
Sangamo Therapeutics, Inc. |
Targeted disruption of the T cell receptor
|
|
JP2018537112A
(ja)
|
2015-12-18 |
2018-12-20 |
サンガモ セラピューティクス, インコーポレイテッド |
Mhc細胞受容体の標的化破壊
|
|
WO2017123757A1
(en)
|
2016-01-15 |
2017-07-20 |
Sangamo Therapeutics, Inc. |
Methods and compositions for the treatment of neurologic disease
|
|
CN109069568B
(zh)
|
2016-02-02 |
2023-07-07 |
桑格摩生物治疗股份有限公司 |
用于连接dna结合结构域和切割结构域的组合物
|
|
WO2017205846A1
(en)
|
2016-05-27 |
2017-11-30 |
Aadigen, Llc |
Peptides and nanoparticles for intracellular delivery of genome-editing molecules
|
|
EP4219462A1
(de)
|
2016-07-13 |
2023-08-02 |
Vertex Pharmaceuticals Incorporated |
Verfahren, zusammensetzungen und kits zur erhöhung der genomeditierungseffizienz
|
|
KR20250103795A
(ko)
|
2016-08-03 |
2025-07-07 |
프레지던트 앤드 펠로우즈 오브 하바드 칼리지 |
아데노신 핵염기 편집제 및 그의 용도
|
|
CA3033327A1
(en)
|
2016-08-09 |
2018-02-15 |
President And Fellows Of Harvard College |
Programmable cas9-recombinase fusion proteins and uses thereof
|
|
AU2017315406B2
(en)
|
2016-08-24 |
2021-04-01 |
Sangamo Therapeutics, Inc. |
Regulation of gene expression using engineered nucleases
|
|
IL264792B2
(en)
|
2016-08-24 |
2023-10-01 |
Sangamo Therapeutics Inc |
Engineered target-specific zinc-finger nucleases
|
|
WO2018039438A1
(en)
|
2016-08-24 |
2018-03-01 |
President And Fellows Of Harvard College |
Incorporation of unnatural amino acids into proteins using base editing
|
|
US10960085B2
(en)
|
2016-09-07 |
2021-03-30 |
Sangamo Therapeutics, Inc. |
Modulation of liver genes
|
|
WO2018067826A1
(en)
|
2016-10-05 |
2018-04-12 |
Cellular Dynamics International, Inc. |
Generating mature lineages from induced pluripotent stem cells with mecp2 disruption
|
|
ES2939646T3
(es)
|
2016-10-13 |
2023-04-25 |
Juno Therapeutics Inc |
Métodos y composiciones de inmunoterapia que comprenden moduladores de la vía metabólica del triptófano
|
|
CN110290813A
(zh)
|
2016-10-14 |
2019-09-27 |
通用医疗公司 |
表观遗传学调控的位点特异性核酸酶
|
|
JP7588390B2
(ja)
|
2016-10-14 |
2024-11-22 |
プレジデント アンド フェローズ オブ ハーバード カレッジ |
核酸塩基エディターのaav送達
|
|
US11219695B2
(en)
|
2016-10-20 |
2022-01-11 |
Sangamo Therapeutics, Inc. |
Methods and compositions for the treatment of Fabry disease
|
|
EP3532106A4
(de)
|
2016-10-31 |
2020-06-24 |
Sangamo Therapeutics, Inc. |
Genkorrektur von scid-assoziierten genen bei hämotopoietischen stammzellen und vorläuferzellen
|
|
AU2017367722B2
(en)
|
2016-12-01 |
2024-02-01 |
Sangamo Therapeutics, Inc. |
Tau modulators and methods and compositions for delivery thereof
|
|
EP3548622A1
(de)
|
2016-12-02 |
2019-10-09 |
Juno Therapeutics, Inc. |
Manipulierte b-zellen sowie zugehörige zusammensetzungen und verfahren
|
|
ES2968892T3
(es)
|
2016-12-08 |
2024-05-14 |
Univ Case Western Reserve |
Métodos y composiciones para aumentar la producción de mielina funcional
|
|
WO2018119359A1
(en)
|
2016-12-23 |
2018-06-28 |
President And Fellows Of Harvard College |
Editing of ccr5 receptor gene to protect against hiv infection
|
|
TW201839136A
(zh)
|
2017-02-06 |
2018-11-01 |
瑞士商諾華公司 |
治療血色素異常症之組合物及方法
|
|
CN110662556A
(zh)
|
2017-03-09 |
2020-01-07 |
哈佛大学的校长及成员们 |
癌症疫苗
|
|
WO2018165504A1
(en)
|
2017-03-09 |
2018-09-13 |
President And Fellows Of Harvard College |
Suppression of pain by gene editing
|
|
JP2020510439A
(ja)
|
2017-03-10 |
2020-04-09 |
プレジデント アンド フェローズ オブ ハーバード カレッジ |
シトシンからグアニンへの塩基編集因子
|
|
BR112019019655A2
(pt)
|
2017-03-23 |
2020-04-22 |
Harvard College |
editores de nucleobase que compreendem proteínas de ligação a dna programáveis por ácido nucleico
|
|
CN117821509A
(zh)
|
2017-04-03 |
2024-04-05 |
编码治疗公司 |
组织选择性转基因表达
|
|
ES2981244T3
(es)
|
2017-04-28 |
2024-10-07 |
Acuitas Therapeutics Inc |
Novedosas formulaciones de nanopartículas de lípidos de carbonilo y lípidos para la administración de ácidos nucleicos
|
|
EP4400175A3
(de)
|
2017-04-28 |
2024-09-25 |
The Regents of the University of Colorado, a body corporate |
Verfahren zur behandlung von rheumatoider arthritis mit rna-geführter genombearbeitung des hla-gens
|
|
CA3059793A1
(en)
|
2017-05-03 |
2018-11-08 |
Sangamo Therapeutics, Inc. |
Methods and compositions for modification of a cystic fibrosis transmembrane conductance regulator (cftr) gene
|
|
WO2018209320A1
(en)
|
2017-05-12 |
2018-11-15 |
President And Fellows Of Harvard College |
Aptazyme-embedded guide rnas for use with crispr-cas9 in genome editing and transcriptional activation
|
|
JP7324713B2
(ja)
|
2017-05-25 |
2023-08-10 |
ザ ジェネラル ホスピタル コーポレイション |
改善された精度および特異性を有する塩基エディター
|
|
US11512287B2
(en)
|
2017-06-16 |
2022-11-29 |
Sangamo Therapeutics, Inc. |
Targeted disruption of T cell and/or HLA receptors
|
|
AU2018302098A1
(en)
|
2017-07-18 |
2020-02-20 |
Csl Behring Gene Therapy, Inc. |
Compositions and methods for treating beta-hemoglobinopathies
|
|
JP2020534795A
(ja)
|
2017-07-28 |
2020-12-03 |
プレジデント アンド フェローズ オブ ハーバード カレッジ |
ファージによって支援される連続的進化(pace)を用いて塩基編集因子を進化させるための方法および組成物
|
|
US11319532B2
(en)
|
2017-08-30 |
2022-05-03 |
President And Fellows Of Harvard College |
High efficiency base editors comprising Gam
|
|
KR20250107288A
(ko)
|
2017-10-16 |
2025-07-11 |
더 브로드 인스티튜트, 인코퍼레이티드 |
아데노신 염기 편집제의 용도
|
|
CN111565730B
(zh)
|
2017-11-09 |
2024-09-17 |
桑格摩生物治疗股份有限公司 |
细胞因子诱导型含sh2蛋白(cish)基因的遗传修饰
|
|
AU2018375192B2
(en)
|
2017-12-01 |
2023-11-09 |
Encoded Therapeutics, Inc. |
Engineered DNA binding proteins
|
|
WO2019118949A1
(en)
|
2017-12-15 |
2019-06-20 |
The Broad Institute, Inc. |
Systems and methods for predicting repair outcomes in genetic engineering
|
|
ES2980444T3
(es)
|
2018-01-17 |
2024-10-01 |
Vertex Pharma |
Inhibidores de ADN-PK
|
|
CN111770921B
(zh)
|
2018-01-17 |
2024-03-22 |
沃泰克斯药物股份有限公司 |
用于提高基因组编辑效率的喹喔啉酮化合物,组合物,方法和试剂盒
|
|
US12121524B2
(en)
|
2018-01-17 |
2024-10-22 |
Vertex Pharmaceuticals Incorporated |
DNA-PK inhibitors
|
|
BR112020015488A2
(pt)
|
2018-02-08 |
2020-12-08 |
Sangamo Therapeutics, Inc. |
Nucleases alvo-específicas modificadas
|
|
EP3775237A1
(de)
|
2018-04-05 |
2021-02-17 |
Juno Therapeutics, Inc. |
T-zellen, die einen rekombinanten rezeptor exprimieren, verwandte polynukleotide und verfahren
|
|
MA52656A
(fr)
|
2018-04-05 |
2021-02-17 |
Editas Medicine Inc |
Procédés de production de cellules exprimant un récepteur recombinant et compositions associées
|
|
US11421007B2
(en)
|
2018-04-18 |
2022-08-23 |
Sangamo Therapeutics, Inc. |
Zinc finger protein compositions for modulation of huntingtin (Htt)
|
|
AU2019266326A1
(en)
|
2018-05-11 |
2020-11-26 |
Beam Therapeutics Inc. |
Methods of editing single nucleotide polymorphism using programmable base editor systems
|
|
US11690921B2
(en)
|
2018-05-18 |
2023-07-04 |
Sangamo Therapeutics, Inc. |
Delivery of target specific nucleases
|
|
WO2019226953A1
(en)
|
2018-05-23 |
2019-11-28 |
The Broad Institute, Inc. |
Base editors and uses thereof
|
|
KR102894715B1
(ko)
|
2018-08-03 |
2025-12-03 |
빔 테라퓨틱스, 인크. |
핵산 표적 서열을 변형시키기 위한 다중-이펙터 핵염기 편집기 및 이를 이용하는 방법
|
|
US11834686B2
(en)
|
2018-08-23 |
2023-12-05 |
Sangamo Therapeutics, Inc. |
Engineered target specific base editors
|
|
US20210348177A1
(en)
|
2018-09-05 |
2021-11-11 |
The Regents Of The University Of California |
Generation of heritably gene-edited plants without tissue culture
|
|
JP2022500052A
(ja)
|
2018-09-18 |
2022-01-04 |
サンガモ セラピューティクス, インコーポレイテッド |
プログラム細胞死1(pd1)特異的ヌクレアーゼ
|
|
IL281615B1
(en)
|
2018-09-21 |
2025-09-01 |
Acuitas Therapeutics Inc |
Systems and methods for producing lipid nanoparticles and liposomes
|
|
CN113226333A
(zh)
|
2018-10-02 |
2021-08-06 |
桑格摩生物治疗股份有限公司 |
用于调控Tau蛋白的方法和组合物
|
|
WO2020092453A1
(en)
|
2018-10-29 |
2020-05-07 |
The Broad Institute, Inc. |
Nucleobase editors comprising geocas9 and uses thereof
|
|
US20220282275A1
(en)
|
2018-11-15 |
2022-09-08 |
The Broad Institute, Inc. |
G-to-t base editors and uses thereof
|
|
JP2022510634A
(ja)
|
2018-11-28 |
2022-01-27 |
フォーティ セブン, インコーポレイテッド |
除去レジメンに抵抗性の遺伝的に改変されたhspc
|
|
KR20210104835A
(ko)
|
2018-12-19 |
2021-08-25 |
누클레인, 엘엘씨 |
분자 진단을 위한 장치 및 방법
|
|
EP3908291A4
(de)
|
2019-01-07 |
2023-01-11 |
Dana-Farber Cancer Institute, Inc. |
Niedermolekulare degrader von fkbp12 über rekrutierung der von-hippel-lindau-e3-ubiquitin-ligase (vhl) und verwendung in dtag-systemen
|
|
AU2020205717B2
(en)
|
2019-01-11 |
2025-09-11 |
Acuitas Therapeutics, Inc. |
Lipids for lipid nanoparticle delivery of active agents
|
|
US12351837B2
(en)
|
2019-01-23 |
2025-07-08 |
The Broad Institute, Inc. |
Supernegatively charged proteins and uses thereof
|
|
WO2020163396A1
(en)
|
2019-02-04 |
2020-08-13 |
The General Hospital Corporation |
Adenine dna base editor variants with reduced off-target rna editing
|
|
WO2020163017A1
(en)
|
2019-02-06 |
2020-08-13 |
Klogenix Llc |
Dna binding proteins and uses thereof
|
|
CA3106693A1
(en)
|
2019-02-06 |
2020-08-13 |
Sangamo Therapeutics, Inc. |
Method for the treatment of mucopolysaccharidosis type i
|
|
WO2020181180A1
(en)
|
2019-03-06 |
2020-09-10 |
The Broad Institute, Inc. |
A:t to c:g base editors and uses thereof
|
|
WO2020181195A1
(en)
|
2019-03-06 |
2020-09-10 |
The Broad Institute, Inc. |
T:a to a:t base editing through adenine excision
|
|
WO2020181202A1
(en)
|
2019-03-06 |
2020-09-10 |
The Broad Institute, Inc. |
A:t to t:a base editing through adenine deamination and oxidation
|
|
WO2020181178A1
(en)
|
2019-03-06 |
2020-09-10 |
The Broad Institute, Inc. |
T:a to a:t base editing through thymine alkylation
|
|
US20220170013A1
(en)
|
2019-03-06 |
2022-06-02 |
The Broad Institute, Inc. |
T:a to a:t base editing through adenosine methylation
|
|
EP3942042A1
(de)
|
2019-03-19 |
2022-01-26 |
The Broad Institute, Inc. |
Verfahren und zusammensetzungen zur editierung von nukleotidsequenzen
|
|
MA55531A
(fr)
|
2019-04-02 |
2022-02-09 |
Sangamo Therapeutics Inc |
Procédés pour le traitement de béta-thalassémie
|
|
CA3136119A1
(en)
|
2019-04-10 |
2020-10-15 |
University Of Utah Research Foundation |
Htra1 modulation for treatment of amd
|
|
EP3956349A1
(de)
|
2019-04-17 |
2022-02-23 |
The Broad Institute, Inc. |
Adeninbaseneditoren mit reduzierten off-target-effekten
|
|
MX2021012836A
(es)
|
2019-04-23 |
2021-12-10 |
Sangamo Therapeutics Inc |
Moduladores de la expresion del gen del marco de lectura abierto 72 del cromosoma 9 y usos de los mismos.
|
|
CN114007640A
(zh)
|
2019-05-01 |
2022-02-01 |
朱诺治疗学股份有限公司 |
从修饰的cd247基因座表达嵌合受体的细胞、相关多核苷酸和方法
|
|
US20220184131A1
(en)
|
2019-05-01 |
2022-06-16 |
Juno Therapeutics, Inc. |
Cells expressing a recombinant receptor from a modified tgfbr2 locus, related polynucleotides and methods
|
|
US12344850B2
(en)
|
2019-07-30 |
2025-07-01 |
Pairwise Plants Services, Inc. |
Morphogenic regulators and methods of using the same
|
|
WO2021022223A1
(en)
|
2019-08-01 |
2021-02-04 |
Sana Biotechnology, Inc. |
Dux4 expressing cells and uses thereof
|
|
WO2021030666A1
(en)
|
2019-08-15 |
2021-02-18 |
The Broad Institute, Inc. |
Base editing by transglycosylation
|
|
JP7728747B2
(ja)
|
2019-08-23 |
2025-08-25 |
サナ バイオテクノロジー,インコーポレイテッド |
Cd24発現細胞およびそれらの用途
|
|
US12435330B2
(en)
|
2019-10-10 |
2025-10-07 |
The Broad Institute, Inc. |
Methods and compositions for prime editing RNA
|
|
EP3812472B1
(de)
|
2019-10-21 |
2022-11-23 |
Albert-Ludwigs-Universität Freiburg |
In-vitro-test zum profilieren der off-target-aktivität eines oder mehrerer zielspezifischer programmierbarer nukleasen in zellen (abnoba-seq)
|
|
TW202132565A
(zh)
|
2019-11-01 |
2021-09-01 |
美商聖加莫治療股份有限公司 |
Gin重組酶變異體
|
|
JP2022553828A
(ja)
|
2019-11-01 |
2022-12-26 |
サンガモ セラピューティクス, インコーポレイテッド |
ゲノム操作のための組成物および方法
|
|
US20230086199A1
(en)
|
2019-11-26 |
2023-03-23 |
The Broad Institute, Inc. |
Systems and methods for evaluating cas9-independent off-target editing of nucleic acids
|
|
US20230235309A1
(en)
|
2020-02-05 |
2023-07-27 |
The Broad Institute, Inc. |
Adenine base editors and uses thereof
|
|
MX2022010991A
(es)
|
2020-03-04 |
2023-02-09 |
Flagship Pioneering Innovations Vi Llc |
Metodos y composiciones para modular un genoma.
|
|
BR112022019060A2
(pt)
|
2020-03-25 |
2022-11-29 |
Sana Biotechnology Inc |
Células neurais hipoimunogênicas para o tratamento de distúrbios e condições neurológicas
|
|
US11091524B1
(en)
|
2020-04-22 |
2021-08-17 |
Houston Gene Therapeutics Llc |
Compositions for treatment of vascular disease
|
|
US20230159913A1
(en)
|
2020-04-28 |
2023-05-25 |
The Broad Institute, Inc. |
Targeted base editing of the ush2a gene
|
|
EP4146812A1
(de)
|
2020-05-06 |
2023-03-15 |
Cellectis S.A. |
Verfahren zur gezielten einführung exogener sequenzen in zelluläre genome
|
|
WO2021224416A1
(en)
|
2020-05-06 |
2021-11-11 |
Cellectis S.A. |
Methods to genetically modify cells for delivery of therapeutic proteins
|
|
CN111549061A
(zh)
*
|
2020-05-07 |
2020-08-18 |
西南大学 |
一种高通量筛选真核生物细胞响应环境极端pH的靶点基因的方法
|
|
WO2021226558A1
(en)
|
2020-05-08 |
2021-11-11 |
The Broad Institute, Inc. |
Methods and compositions for simultaneous editing of both strands of a target double-stranded nucleotide sequence
|
|
JP2023526278A
(ja)
|
2020-05-13 |
2023-06-21 |
ジュノー セラピューティクス インコーポレイテッド |
組み換え受容体を発現しているドナーバッチ細胞を産生するための方法
|
|
WO2021236852A1
(en)
|
2020-05-20 |
2021-11-25 |
Sana Biotechnology, Inc. |
Methods and compositions for treatment of viral infections
|
|
KR20230042283A
(ko)
|
2020-06-26 |
2023-03-28 |
주노 테라퓨틱스 게엠베하 |
재조합 수용체를 조건부로 발현하는 조작된 t 세포, 관련된 폴리뉴클레오티드 및 방법
|
|
CA3189338A1
(en)
|
2020-07-16 |
2022-01-20 |
Acuitas Therapeutics, Inc. |
Cationic lipids for use in lipid nanoparticles
|
|
US20220049226A1
(en)
|
2020-08-13 |
2022-02-17 |
Sana Biotechnology, Inc. |
Methods of treating sensitized patients with hypoimmunogenic cells, and associated methods and compositions
|
|
EP4501951A3
(de)
|
2020-08-25 |
2025-04-30 |
Kite Pharma, Inc. |
T-zellen mit verbesserter funktionalität
|
|
EP4240756A1
(de)
|
2020-11-04 |
2023-09-13 |
Juno Therapeutics, Inc. |
Zellen zur expression eines chimären rezeptors aus einem modifizierten invarianten kettenlocus der cd3-immunglobulin-superfamilie und zugehörige polynukleotide und verfahren
|
|
EP4243609A1
(de)
|
2020-11-16 |
2023-09-20 |
Pig Improvement Company UK Limited |
Influenza-a-resistente tiere mit bearbeiteten anp32-genen
|
|
IL303473A
(en)
|
2020-12-31 |
2023-08-01 |
Sana Biotechnology Inc |
Methods and compositions for modulating car-t activity
|
|
CN116981697A
(zh)
|
2021-01-14 |
2023-10-31 |
森迪生物科学公司 |
可分泌有效载荷调节
|
|
WO2022178307A1
(en)
|
2021-02-19 |
2022-08-25 |
Beam Therapeutics Inc. |
Recombinant rabies viruses for gene therapy
|
|
CN118019546A
(zh)
|
2021-03-23 |
2024-05-10 |
艾欧凡斯生物治疗公司 |
肿瘤浸润淋巴细胞的cish基因编辑及其在免疫疗法中的用途
|
|
CA3216346A1
(en)
|
2021-05-27 |
2022-12-01 |
Edward Rebar |
Hypoimmunogenic cells comprising engineered hla-e or hla-g
|
|
CA3225283A1
(en)
|
2021-07-14 |
2023-01-19 |
Sonja SCHREPFER |
Altered expression of y chromosome-linked antigens in hypoimmunogenic cells
|
|
JP2024534772A
(ja)
|
2021-08-11 |
2024-09-26 |
サナ バイオテクノロジー,インコーポレイテッド |
同種異系細胞療法用の遺伝子改変細胞
|
|
AU2022325232A1
(en)
|
2021-08-11 |
2024-02-08 |
Sana Biotechnology, Inc. |
Genetically modified primary cells for allogeneic cell therapy
|
|
CA3227613A1
(en)
|
2021-08-11 |
2023-02-16 |
William Dowdle |
Inducible systems for altering gene expression in hypoimmunogenic cells
|
|
EP4384193A2
(de)
|
2021-08-11 |
2024-06-19 |
Sana Biotechnology, Inc. |
Genetisch modifizierte zellen für allogene zelltherapie zur reduzierung von durch instant-blut vermittelten entzündungsreaktionen
|
|
US20240425820A1
(en)
|
2021-08-11 |
2024-12-26 |
Sana Biotechnology, Inc. |
Genetically modified cells for allogeneic cell therapy to reduce complement-mediated inflammatory reactions
|
|
US12305184B2
(en)
|
2021-09-03 |
2025-05-20 |
North Carolina State University |
Compositions and methods for conferring resistance to geminivirus
|
|
JP2024533311A
(ja)
|
2021-09-08 |
2024-09-12 |
フラッグシップ パイオニアリング イノベーションズ シックス,エルエルシー |
ゲノムを調節するための方法及び組成物
|
|
AU2022343725A1
(en)
|
2021-09-08 |
2024-03-21 |
Beam Therapeutics Inc. |
Viral guide rna delivery
|
|
WO2023069790A1
(en)
|
2021-10-22 |
2023-04-27 |
Sana Biotechnology, Inc. |
Methods of engineering allogeneic t cells with a transgene in a tcr locus and associated compositions and methods
|
|
CA3237482A1
(en)
|
2021-11-03 |
2023-05-11 |
The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone |
Precise genome editing using retrons
|
|
WO2023081900A1
(en)
|
2021-11-08 |
2023-05-11 |
Juno Therapeutics, Inc. |
Engineered t cells expressing a recombinant t cell receptor (tcr) and related systems and methods
|
|
WO2023105244A1
(en)
|
2021-12-10 |
2023-06-15 |
Pig Improvement Company Uk Limited |
Editing tmprss2/4 for disease resistance in livestock
|
|
WO2023114943A2
(en)
|
2021-12-16 |
2023-06-22 |
Acuitas Therapeutics, Inc. |
Lipids for use in lipid nanoparticle formulations
|
|
MX2024007528A
(es)
|
2021-12-23 |
2024-08-30 |
Sana Biotechnology Inc |
Linfocitos t del receptor de antígeno quimérico (car) para el tratamiento de enfermedades autoinmunitarias y métodos asociados.
|
|
WO2023141602A2
(en)
|
2022-01-21 |
2023-07-27 |
Renagade Therapeutics Management Inc. |
Engineered retrons and methods of use
|
|
US20250302953A1
(en)
|
2022-02-14 |
2025-10-02 |
Sana Biotechnology, Inc. |
Methods of treating patients exhibiting a prior failed therapy with hypoimmunogenic cells
|
|
IL315000A
(en)
|
2022-02-17 |
2024-10-01 |
Sana Biotechnology Inc |
Engineered cd47 proteins and uses thereof
|
|
US20250101382A1
(en)
|
2022-03-11 |
2025-03-27 |
Sana Biotechnology, Inc. |
Genetically modified cells and compositions and uses thereof
|
|
EP4522210A1
(de)
|
2022-05-09 |
2025-03-19 |
Synteny Therapeutics, Inc. |
Erythroparvovirus mit modifiziertem genom zur gentherapie
|
|
EP4522201A1
(de)
|
2022-05-09 |
2025-03-19 |
Synteny Therapeutics, Inc. |
Erythroparvoviruszusammensetzungen und verfahren zur gentherapie
|
|
EP4522203A1
(de)
|
2022-05-09 |
2025-03-19 |
Synteny Therapeutics, Inc. |
Erythroparvovirus mit modifiziertem kapsid zur gentherapie
|
|
WO2024013514A2
(en)
|
2022-07-15 |
2024-01-18 |
Pig Improvement Company Uk Limited |
Gene edited livestock animals having coronavirus resistance
|
|
JP2025531669A
(ja)
|
2022-08-16 |
2025-09-25 |
ザ ブロード インスティテュート,インコーポレーテッド |
進化したシチジンデアミナーゼおよびそれを使用してdnaを編集する方法
|
|
WO2024044723A1
(en)
|
2022-08-25 |
2024-02-29 |
Renagade Therapeutics Management Inc. |
Engineered retrons and methods of use
|
|
EP4615960A1
(de)
|
2022-11-09 |
2025-09-17 |
C3S2 GmbH |
Verfahren zur herstellung von manipulierten immunzellen
|
|
WO2024151541A1
(en)
|
2023-01-09 |
2024-07-18 |
Sana Biotechnology, Inc. |
Type-1 diabetes autoimmune mouse
|
|
WO2024155745A1
(en)
|
2023-01-18 |
2024-07-25 |
The Broad Institute, Inc. |
Base editing-mediated readthrough of premature termination codons (bert)
|
|
CN121002052A
(zh)
|
2023-02-03 |
2025-11-21 |
C3S2 有限公司 |
用于非病毒生产工程化免疫细胞的方法
|
|
WO2024187174A2
(en)
|
2023-03-09 |
2024-09-12 |
Aadigen, Llc |
Compositions for treating cancer with kras mutations and uses thereof
|
|
US12383615B2
(en)
|
2023-03-23 |
2025-08-12 |
Carbon Biosciences, Inc. |
Protoparvovirus compositions comprising a protoparvovirus variant VP1 capsid polypeptide and related methods
|
|
WO2024229302A1
(en)
|
2023-05-03 |
2024-11-07 |
Sana Biotechnology, Inc. |
Methods of dosing and administration of engineered islet cells
|
|
WO2024238723A1
(en)
|
2023-05-16 |
2024-11-21 |
Omega Therapeutics, Inc. |
Methods and compositions for modulating pcsk9 expression
|
|
WO2024238726A1
(en)
|
2023-05-16 |
2024-11-21 |
Omega Therapeutics, Inc. |
Methods and compositions for modulating methylation of a target gene
|
|
WO2024243236A2
(en)
|
2023-05-22 |
2024-11-28 |
Sana Biotechnology, Inc. |
Methods of delivery of islet cells and related methods
|
|
WO2025004001A1
(en)
|
2023-06-30 |
2025-01-02 |
Takeda Pharmaceutical Company Limited |
Htt repressors and uses thereof
|
|
WO2025019742A1
(en)
|
2023-07-19 |
2025-01-23 |
Omega Therapeutics, Inc. |
Methods and compositions for modulating ctnnb1 expression
|
|
WO2025049959A2
(en)
|
2023-09-01 |
2025-03-06 |
Renagade Therapeutics Management Inc. |
Gene editing systems, compositions, and methods for treatment of vexas syndrome
|
|
WO2025064469A1
(en)
|
2023-09-18 |
2025-03-27 |
Omega Therapeutics, Inc. |
Methods for assessing dosage for epigenetic modifying agents
|
|
WO2025174765A1
(en)
|
2024-02-12 |
2025-08-21 |
Renagade Therapeutics Management Inc. |
Lipid nanoparticles comprising coding rna molecules for use in gene editing and as vaccines and therapeutic agents
|
|
WO2025193628A2
(en)
|
2024-03-09 |
2025-09-18 |
Aadigen, Llc |
Compositions for treating cancer with kras mutations and uses thereof
|
|
WO2025194124A1
(en)
|
2024-03-14 |
2025-09-18 |
Tessera Therapeutics, Inc. |
Modified st1cas9 guide nucleic acids
|
|
WO2025235563A1
(en)
|
2024-05-07 |
2025-11-13 |
Omega Therapeutics, Inc. |
Epigenetic modulation for upregulation of genes
|
|
WO2025235851A1
(en)
|
2024-05-10 |
2025-11-13 |
Juno Therapeutics, Inc. |
Genetically engineered t cells expressing a cd19 chimeric antigen receptor (car) and uses thereof for allogeneic cell therapy
|